Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 25;44(2):115298.
doi: 10.1016/j.celrep.2025.115298. Epub 2025 Feb 11.

Cellular rejuvenation protects neurons from inflammation-mediated cell death

Affiliations

Cellular rejuvenation protects neurons from inflammation-mediated cell death

Sienna S Drake et al. Cell Rep. .

Abstract

In multiple sclerosis (MS), inflammation of the central nervous system results in demyelination, neuroaxonal injury, and cell death. However, the molecular signals responsible for injury and cell death in neurons are not fully characterized. Here, we profile the transcriptome of retinal ganglion cells (RGCs) in experimental autoimmune encephalomyelitis (EAE) mice. Pathway analysis identifies a transcriptional signature reminiscent of aged RGCs with some senescent features, with a comparable signature present in neurons from patients with MS. This is supported by immunostaining demonstrating alterations to the nuclear envelope, modifications in chromatin marks, and accumulation of DNA damage. Transduction of RGCs with an Oct4-Sox2-Klf4 adeno-associated virus (AAV) to rejuvenate the transcriptome enhances RGC survival in EAE and improves visual acuity. Collectively, these data reveal an aging-like phenotype in neurons under pathological neuroinflammation and support the possibility that rejuvenation therapies or senotherapeutic agents could offer a direct avenue for neuroprotection in neuroimmune disorders.

Keywords: AAV-OSK; ATAC sequencing; CP: Neuroscience; RNA sequencing; aging; experimental autoimmune encephalomyelitis; multiple sclerosis; neurodegeneration; partial reprogramming; rejuvenation; senescence.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.A.S. has equity and consults for Life Biosciences, a company developing rejuvenation medicines. For more information, see https://sinclair.hms.harvard.edu/david-sinclairs-affiliations. Y.R.L. holds patents licensed to and minor equity in Life Biosciences.

Update of

MeSH terms